Abstract:Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma of the lung that accounts for only 1% to 3% of all lung cancers and was re-classified as a distinct neuroendocrine group. There is an emerging need for an agreement on the best strategy for managing pulmonary LCNEC. Here, we reviewed our institutional experiences and tried to suggest the appropriate treatment directions for resectable pulmonary LCNEC. A total of 72 patients were pathologically diagnosed as pulmonary LCNEC between January 2005 and December 2018 in the Yonsei cancer center. We considered curative surgery first for patients with early-stage tumors or some advanced-stage tumors with resectable status, unless they were medically inoperable. Adjuvant treatment option was decided after considering each patient’s clinical and pathologic features. Consequently, 39 patients with stage I to III LCNEC (I: 18, II: 12, III: 9) underwent curative resection of the primary tumor, and these patients were included in this study cohort. In stage I, 6 (33%) patients received surgery alone, and 12 (67%) patients received adjuvant chemotherapy. In stage II, 2 (17%) patients received surgery alone and 10 (83%) patients received adjuvant chemotherapy. In stage III, only 1 (11%) patient received surgery alone, and 8 (89%) received adjuvant treatment, include 6 with adjuvant chemotherapy, 2 with sequential chemotherapy and radiotherapy (RT), and 1 with adjuvant concurrent chemoradiotherapy. With a median follow-up of 30 months, the median overall survival (OS) was 58.8 months and 3-year, 5-year rates were 58% and 47%, respectively. The median recurrence-free survival (RFS) was 24 months and 3-, and 5-year rates were 47% and 39%, respectively. In the univariate analysis for OS, older age (≥67) and SCLC-mixed histology were poor prognostic factors (p = 0.019, p = 0.001 (vs. pure LCNEC), and 0.015 (vs. NSCLC-mixed)), respectively. These 2 factors were independently associated with OS also in multivariate analysis (p = 0.036, 0.003, and 0.015). SCLC-mixed histology was the only significant factor for poor RFS. In the entire cohort, recurrences occur in 17 patients (44%). Most of the recurrence patterns were very extensive even at first recurrence; 14 distant metastases (m/c, 82%), 8 local recurrences, and 8 regional (all mediastinal lymph node) recurrences. Our study demonstrated that surgery ± adjuvant treatment could achieve favorable survival outcomes in pulmonary LCNEC. Some factors such as older age and mixed histology with SCLC made the overall prognosis worse, regardless of the stage, which proposed the need for adjuvant treatment strategies by a multidisciplinary approach. More aggressive treatments than NSCLC as mediastinal RT for node-positive patients, new chemotherapy regimens, or prophylactic cranial irradiation could be considered. Further studies in a larger cohort would be needed to draw more definitive conclusions.

Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature

Combined Large Cell Neuroendocrine Carcinoma: Clinical Characteristics, Prognosis and Postoperative Management

Combined large‑cell neuroendocrine carcinoma and small‑cell lung cancer: A case report

Large Cell Neuroendocrine Carcinoma Of The Lungs: Case Report And Literature Review

Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study.

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Case Report: Combined Small Cell Lung Carcinoma with Pulmonary Adenocarcinoma.

Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study

Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung

Endometrial large cell neuroendocrine carcinoma: A case report and literature review

1114P Comparative Study of Combined Large Cell Neuroendocrine Carcinoma and Combined Small Cell Carcinoma in Resected High-Grade Neuroendocrine Tumors of the Lung

Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges

P1.07-036 Large Cell Neuroendocrine Carcinoma of the Lung: the Mayo Clinic Experience

Genomic Feature of a Rare Case of Mix Small-Cell and Large-Cell Neuroendocrine Lung Carcinoma: A Case Report

Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis

Clinical analysis of 88 cases with combined small cell carcinoma

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung

PO-1032: Clinical Features and Treatment Outcome of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma

Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study